

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of Sinopharm Group Co. Ltd. (the “**Company**”) dated 18 March 2022 (the “**Announcement**”) in relation to, among others, proposed ratification of the 2021 Actual Transaction Amounts and proposed revision of the annual caps for 2022 and 2023 for the transactions contemplated under the 2020 Procurement Framework Agreement and the 2020 Sales Framework Agreement. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as defined in the Announcement.

As additional time is required for the Company to prepare and finalize certain information in the Circular, the despatch date of the Circular is expected to be postponed from the date originally scheduled to on or before 13 May 2022. The arrangements of the EGM originally scheduled on 11 May 2022 are expected to be changed and the Company will announce the latest arrangements for the EGM in due course.

By order of the Board
Sinopharm Group Co. Ltd.
Yu Qingming
Chairman

Shanghai, the PRC

27 April 2022

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Ma Ping, Mr. Deng Jindong, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.

**The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”*